DE122011000004I1 - Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION - Google Patents

Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION

Info

Publication number
DE122011000004I1
DE122011000004I1 DE122011000004C DE122011000004C DE122011000004I1 DE 122011000004 I1 DE122011000004 I1 DE 122011000004I1 DE 122011000004 C DE122011000004 C DE 122011000004C DE 122011000004 C DE122011000004 C DE 122011000004C DE 122011000004 I1 DE122011000004 I1 DE 122011000004I1
Authority
DE
Germany
Prior art keywords
pct
person
asthma
susceptibility
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122011000004C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sydney West Area Health Service SWAHS
Original Assignee
Sydney West Area Health Service SWAHS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sydney West Area Health Service SWAHS filed Critical Sydney West Area Health Service SWAHS
Publication of DE122011000004I1 publication Critical patent/DE122011000004I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
DE122011000004C 1994-02-25 1995-02-23 Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION Pending DE122011000004I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM4114A AUPM411494A0 (en) 1994-02-25 1994-02-25 Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
PCT/AU1995/000086 WO1995022993A1 (en) 1994-02-25 1995-02-23 Method and device for the provocation of air passage narrowing and/or the induction of sputum

Publications (1)

Publication Number Publication Date
DE122011000004I1 true DE122011000004I1 (de) 2011-05-05

Family

ID=3778730

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122011000004C Pending DE122011000004I1 (de) 1994-02-25 1995-02-23 Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION
DE69536090T Expired - Lifetime DE69536090D1 (de) 1994-02-25 1995-02-23 Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69536090T Expired - Lifetime DE69536090D1 (de) 1994-02-25 1995-02-23 Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION

Country Status (15)

Country Link
US (1) US5817028A (de)
EP (1) EP0748228B8 (de)
JP (7) JP3979660B2 (de)
KR (1) KR100385675B1 (de)
CN (1) CN1075737C (de)
AT (1) ATE474583T1 (de)
AU (2) AUPM411494A0 (de)
CA (1) CA2183471C (de)
DE (2) DE122011000004I1 (de)
DK (1) DK0748228T3 (de)
ES (1) ES2349027T3 (de)
FR (1) FR11C0002I2 (de)
NZ (1) NZ281522A (de)
PT (1) PT748228E (de)
WO (1) WO1995022993A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
CZ333698A3 (cs) 1996-04-16 1999-01-13 Bayer Ag D-mannitol a způsob jeho přípravy
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP2191718A1 (de) * 1998-12-22 2010-06-02 The University of North Carolina at Chapel Hill Verbindungen und Verwendungen zur Behandlung von Atemwegeserkrankungen sowie zur Verabreichung von Arzneistoffen für die Atemwege
JP5437543B2 (ja) 1999-04-21 2014-03-12 １３５５５４０ オンタリオ インコーポレーテッド 喘息検出用製剤
WO2001062264A2 (en) * 2000-02-23 2001-08-30 The Procter & Gamble Company Halotherapy method by inhalation of sodium chloride
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
GB0014898D0 (en) * 2000-06-19 2000-08-09 Innovata Biomed Ltd Delivery system
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
JP2005535581A (ja) * 2002-05-02 2005-11-24 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肺感染の拡大を制限する処方物
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
EP1906922A2 (de) * 2005-05-18 2008-04-09 Pulmatrix, Inc. Formulierungen zur veränderung biophysikalischer eigenschaften der schleimhautauskleidung
EA200970258A1 (ru) * 2006-09-07 2009-08-28 Пэрион Сайенсиз, Инк. Способ усиления гидратации слизистой оболочки и клиренса слизистой оболочки обработкой блокаторами натриевых каналов и осмолитами
TW200819430A (en) * 2006-09-07 2008-05-01 Michael R Johnson Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US8714153B2 (en) * 2007-04-16 2014-05-06 Ric Investments, Llc Method for selecting a device adapted to treat disordered breathing
EP2211956A4 (de) 2007-10-10 2014-07-09 Parion Sciences Inc Abgabe von osmolyten mit einer nasenkanüle
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
TWI432198B (zh) 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
CN102497853B (zh) 2009-03-26 2018-03-23 普马特里克斯营业公司 治疗肺病的干粉配方与方法
CN104042322B (zh) 2009-10-27 2017-06-06 赫莱拉公司 具有可冷却的能量发射组件的递送装置
MD4039C1 (ro) * 2009-11-05 2010-12-31 Институт Химии Академии Наук Молдовы Microsalină artificială de suprafaţă
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
MD4089C1 (ro) * 2009-11-18 2011-08-31 Институт Химии Академии Наук Молдовы Halocameră artificială de suprafaţă
MD4040C1 (ro) * 2009-12-09 2010-12-31 Институт Химии Академии Наук Молдовы Halocameră artificială de suprafaţă
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6219271B2 (ja) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
PL2855435T3 (pl) 2012-05-29 2018-10-31 Parion Sciences, Inc. Amidy o strukturze podobnej do dendrymerów, wykazujące aktywność blokerów kanałów sodowych, do leczenia zespołu suchego oka i innych chorób śluzówki
US9770293B2 (en) 2012-06-04 2017-09-26 Boston Scientific Scimed, Inc. Systems and methods for treating tissue of a passageway within a body
WO2014018153A1 (en) 2012-07-24 2014-01-30 Boston Scientific Scimed, Inc. Electrodes for tissue treatment
US9272132B2 (en) 2012-11-02 2016-03-01 Boston Scientific Scimed, Inc. Medical device for treating airways and related methods of use
WO2014071372A1 (en) 2012-11-05 2014-05-08 Boston Scientific Scimed, Inc. Devices for delivering energy to body lumens
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
CN105451680B (zh) 2013-08-09 2019-10-08 波士顿科学国际有限公司 可扩张导管以及制造和使用的相关方法
CN104510726A (zh) * 2013-09-27 2015-04-15 张金华 一种用于清洁呼吸道系统的食盐干粉吸入剂
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
KR102288656B1 (ko) 2020-12-02 2021-08-12 순천향대학교 산학협력단 천식 또는 천식 악화 진단용 pcr 키트 및 이를 이용한 천식 또는 천식 악화 진단을 위한 정보의 제공방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623936A (en) * 1979-08-01 1981-03-06 Chest Corp Measuring apparatus of trachea hypersensitivity
WO1981001243A1 (en) * 1979-10-30 1981-05-14 Riker Laboratories Inc Breath actuated devices for administering powdered medicaments
EP0041783B1 (de) * 1980-06-06 1984-12-05 FISONS plc Inhalationsgerät für puderförmige Medikamente
ES506585A0 (es) * 1980-10-30 1982-09-01 Riker Laboratories Inc Un dispositivo para facilitar la inhalacion oral de medica- mentos en forma de polvo
JPS6168418A (ja) * 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
DE3518665C2 (de) * 1985-05-23 1994-03-17 Hoelter Heinz Holzfilter zum Erzeugen von gereinigter und natürlich duftender Atemluft
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
CA1317194C (en) * 1989-05-31 1993-05-04 Yves Cloutier Device for specific inhalation challenge, method of use and improved generator of particules
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
NL9002706A (nl) * 1990-12-10 1992-07-01 Pharmachemie Bv Inrichting ten gebruike bij het inhaleren van in staafvormige capsules verpakte poedervormige stoffen.
GB9101592D0 (en) * 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
AU2746292A (en) * 1991-10-30 1993-05-06 Kenneth Roy Hanson Asthma and other allergies cure
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5558085A (en) * 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
CA2155933C (en) * 1993-02-12 2000-04-04 James L. Levin Pulmonary administration of scr1 and other complement inhibitory proteins
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9408053D0 (en) * 1994-04-22 1994-06-15 Nat Heart & Lung Inst Pharmaceutical preparation
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery

Also Published As

Publication number Publication date
PT748228E (pt) 2010-09-15
EP0748228A4 (de) 1999-12-22
AU1748295A (en) 1995-09-11
DE69536090D1 (de) 2010-09-02
JP2013049708A (ja) 2013-03-14
NZ281522A (en) 1998-09-24
US5817028A (en) 1998-10-06
KR100385675B1 (ko) 2003-10-10
CA2183471A1 (en) 1995-08-31
AUPM411494A0 (en) 1994-03-24
CA2183471C (en) 2008-07-29
EP0748228A1 (de) 1996-12-18
EP0748228B8 (de) 2010-08-25
EP0748228B1 (de) 2010-07-21
ATE474583T1 (de) 2010-08-15
WO1995022993A1 (en) 1995-08-31
FR11C0002I2 (fr) 2016-03-25
FR11C0002I1 (de) 2011-01-25
CN1142190A (zh) 1997-02-05
JP2007056040A (ja) 2007-03-08
JP2011148839A (ja) 2011-08-04
CN1075737C (zh) 2001-12-05
JPH10501790A (ja) 1998-02-17
JP2013136564A (ja) 2013-07-11
JP2011148840A (ja) 2011-08-04
DK0748228T3 (da) 2010-10-11
ES2349027T3 (es) 2010-12-21
AU682756B2 (en) 1997-10-16
JP3979660B2 (ja) 2007-09-19
JP2007056039A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
DE69536090D1 (de) Pulver FÜR DIE PROVOKATION EINER VERENGUNG DER LUFTWEGE UND/ODER DER SPUTUMPRODUKTION
Fubini et al. Chemical aspects of the toxicity of inhaled mineral dusts
Hughes et al. Asbestos exposure—quantitative assessment of risk
Swift et al. Inspiratory deposition of ultrafine particles in human nasal replicate cast
Enterline et al. Respiratory disease among workers exposed to man-made mineral fibers
Koenig et al. Acute effects of inhaled SO2 plus NaCl droplet aerosol on pulmonary function in asthmatic adolescents
Yu et al. Predicted deposition of diesel particles in young humans
Li et al. Wearing time and respiratory volume affect the filtration efficiency of masks against aerosols at different sizes
Chan et al. Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract
MY115838A (en) Method and device for the provocation of air passage narrowing and/or the induction of sputum
Mocek et al. Mine dust-as a cause of respiratory diseases of miners
Polatli et al. Perlite exposure and 4-year change in lung function
Svartengren et al. Regional deposition of particles in human lung after induced bronchoconstriction
Sh Diagnosis and Prevention of Occupational Diseases Caused By Exposure to Industrial Dust
Sankhala et al. Factors that affect the lung deposition
Cohen Occupational lung disease: pneumoconiosis
McAughey et al. Risk assessment of exposure to indoor air pollutants
Hames The Pneumoconioses: Diagnosis, Evaluation, and Management
Rastogi et al. Pulmonary function study in female grinders exposed to agate dust
Scatarige et al. Induction of thoracic malignancy in inorganic dust pneumoconiosis
Kristo et al. The potential for delivery of particulate matter through positive airway pressure devices (CPAP/BPAP)
Nurhayati et al. Analysis of Risk Factors that Affect Pulmonary Function Disorder in the Manufacturing Industry
BRAMAN et al. Occupational lung disease
GABRIEL The occupational environment
Douglas Occupational lung disease and aerosols